single invest


Draupnir Bio has developed a platform for exploring the glycome to develop novel therapeutics. The platform is based on array technology, protein chemistry and advanced carbohydrate chemistry.

Draupnir has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. Draupnir is one of more than 500 companies that Accelerace already have accelerated.

Related startups